- Policy
- Pricing reduction-evading drug relisting to be rejected
- by Kim, Jung-Ju Aug 10, 2020 06:00am
- Now a new regulation would stop companies from attempting to technically relist a drug to avoid pricing reduction. Following the administrative procedure, the newly revised regulation would be enforced from September at earliest. The Regulatory Reform Committee categorized the Ministry of Health and Welfare (MOHW)-revised ‘Regulation on
- Policy
- Pre-approval of benefits for Spinraza were approved
- by Lee, Hye-Kyung Aug 10, 2020 06:00am
- 5 out of 6 cases for pre-approval of benefits for Spinal Muscular Atrophy (SMA) treatment 'Spinraza (Nusinersen)' last month were approved. After approval of Spinraza benefits, a monitoring report must be submitted every four months before administration of maintenance doses, and all 24 cases of administration monitoring have been approv
- Company
- AZ, Takeda and Pfizer to compete in PARP inhibitor market
- by Eo, Yun-Ho Aug 7, 2020 06:28am
- The competition ground among poly ADP ribose polymerase (PARP) inhibitors targeting BRCA gene has widened as Pfizer entered the South Korean market following the footsteps of AstraZeneca and Takeda Pharmaceutical. According to the pharmaceutical industry sources, the Korean health authority approved of Pfizer Korea’s Talzenna (talazopa
- Policy
- Kcab, compared clinical trial with Nexium
- by Lee, Tak-Sun Aug 7, 2020 06:27am
- HK inno.N's new domestic drug ‘Kcab’ is specifically compared with the reference drug, Nexium. The company said it will explore new indications through the trial. The MFDS approved IND of Phase I clinical trial to explore the pharmacokinetics, Pharmacodynamic properties and safety of Tegoprazan twice a day dosing regimen in healthy subj
- Company
- A big deal after various exchanges between companies
- by Lee, Seok-Jun Aug 7, 2020 06:27am
- Big Deal (License Out/LO) of the traditional pharmaceutical companies show that there have been various exchanges in the past. Looking at the recently established Hanmi and Yuhan’s technology transfer partners, it was because there were exchanges such as joint promotion in the past. It was that exchanges in the past led to exchanges between
- Boryung eyes KRW 60 bln multiple myeloma drug market
- by Lee, Tak-Sun Aug 7, 2020 06:27am
- Boryung Pharmaceutical is taking bold actions to expand its share in the South Korea’s multiple myeloma treatment market valued at 60 billion won. After signing a deal to supply a new drug in the Korean pharmaceutical market, the company is now challenging the original Pomalyst’s patent for the first time in Korea. According to the
- Policy
- SNUH participates in COVID-19 trials using Rebif
- by Lee, Tak-Sun Aug 7, 2020 06:27am
- Seoul National University Hospital participates in a multinational clinical trial using 'Rebif' (Interferon Beta-1A, Merck), which has recently been cited as a candidate for COVID-19 treatment. Rebif is a pre-filled injection that is also approved in Korea. It is used for multiple sclerosis, and has recently been mentioned as a candidate f
- Company
- SGLT-2 inhibitors growth surge by 30% in antidiabetic market
- by An, Kyung-Jin Aug 7, 2020 06:26am
- In the South Korean oral antidiabetic drug market, the influence of sodium-glucose cotransporter-2 (SGLT2) inhibitors has expanded even further. The outpatient prescription sales in the medicine broke through the 50-million-won point as the single drug prescription is constantly growing and combination therapies have been effective. AstraZ
- Policy
- Generics was applied in 7 years after Pelrubi’s PMS ended
- by Lee, Tak-Sun Aug 7, 2020 06:26am
- The application for generic for Pelubi was received 7 years after the PMS of the original drug was terminated. There have been reasons for not being able to apply because of patents, but it is an analysis that Pelubi's popularity in the market lately has influenced the generic development of pharmaceutical companies. According to the MFDS
- Company
- Hanmi signed a technology transfer of ₩1 trillion
- by Lee, Seok-Jun Aug 7, 2020 06:26am
- Hanmi signed a technology transfer agreement of &8361;1 trillion ($860 million). The down payment is $10 million (&8361;12 billion), and the other side is MSD, a global US pharmaceutical company. Hanmi announced on the 4th that it has signed a license agreement with MSD to develop, manufacture and commercialize the biomedicine candidate
